Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 3,339 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now directly owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Denali Therapeutics Price Performance

NASDAQ DNLI traded up $0.07 on Wednesday, hitting $21.25. 1,245,656 shares of the company were exchanged, compared to its average volume of 1,173,671. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.33. The firm has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39. The company’s 50 day moving average price is $24.34 and its 200-day moving average price is $24.88.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the business posted ($0.72) EPS. As a group, equities analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Institutional Trading of Denali Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in shares of Denali Therapeutics by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 194,859 shares of the company’s stock valued at $4,525,000 after purchasing an additional 22,900 shares during the period. TD Asset Management Inc increased its stake in Denali Therapeutics by 4.5% in the 2nd quarter. TD Asset Management Inc now owns 179,152 shares of the company’s stock valued at $4,160,000 after buying an additional 7,766 shares during the period. Arizona State Retirement System lifted its position in Denali Therapeutics by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 33,114 shares of the company’s stock worth $769,000 after buying an additional 2,730 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Denali Therapeutics by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 522,594 shares of the company’s stock valued at $12,135,000 after buying an additional 63,058 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company’s stock valued at $32,913,000 after buying an additional 84,522 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Robert W. Baird initiated coverage on Denali Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $31.00 price target on the stock. HC Wainwright dropped their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday. Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Finally, William Blair initiated coverage on shares of Denali Therapeutics in a research report on Friday, January 3rd. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.